149 related articles for article (PubMed ID: 26469723)
1. Immune protection-inducing protein structures (IMPIPS) against malaria: the weapons needed for beating Odysseus.
Patarroyo ME; Patarroyo MA; Pabón L; Curtidor H; Poloche LA
Vaccine; 2015 Dec; 33(52):7525-37. PubMed ID: 26469723
[TBL] [Abstract][Full Text] [Related]
2. Fitting modified HRP-I peptide analogue 3D structure into HLA-DR molecules induces protection against Plasmodium falciparum malaria.
Bermúdez A; Alba P; Espejo F; Vargas LE; Parra C; Rodríguez R; Reyes C; Patarroyo ME
Int J Biochem Cell Biol; 2005 Feb; 37(2):336-49. PubMed ID: 15474979
[TBL] [Abstract][Full Text] [Related]
3. The case for a subunit vaccine against malaria.
Anders RF
Trends Parasitol; 2011 Aug; 27(8):330-4. PubMed ID: 21592861
[TBL] [Abstract][Full Text] [Related]
4. Functional, immunological and three-dimensional analysis of chemically synthesised sporozoite peptides as components of a fully-effective antimalarial vaccine.
Curtidor H; Vanegas M; Alba MP; Patarroyo ME
Curr Med Chem; 2011; 18(29):4470-502. PubMed ID: 22029724
[TBL] [Abstract][Full Text] [Related]
5. Preliminary Evaluation of the Safety and Immunogenicity of an Antimalarial Vaccine Candidate Modified Peptide (IMPIPS) Mixture in a Murine Model.
Lambraño J; Curtidor H; Avendaño C; Díaz-Arévalo D; Roa L; Vanegas M; Patarroyo ME; Patarroyo MA
J Immunol Res; 2019; 2019():3832513. PubMed ID: 32083140
[TBL] [Abstract][Full Text] [Related]
6. Towards the development of a fully protective Plasmodium falciparum antimalarial vaccine.
Patarroyo ME; Bermúdez A; Moreno-Vranich A
Expert Rev Vaccines; 2012 Sep; 11(9):1057-70. PubMed ID: 23151164
[TBL] [Abstract][Full Text] [Related]
7. Erythrocyte and reticulocyte binding-like proteins of Plasmodium falciparum.
Tham WH; Healer J; Cowman AF
Trends Parasitol; 2012 Jan; 28(1):23-30. PubMed ID: 22178537
[TBL] [Abstract][Full Text] [Related]
8. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
Patarroyo ME; Patarroyo MA
Acc Chem Res; 2008 Mar; 41(3):377-86. PubMed ID: 18266328
[TBL] [Abstract][Full Text] [Related]
9. Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization.
Bermúdez A; Reyes C; Guzmán F; Vanegas M; Rosas J; Amador R; Rodríguez R; Patarroyo MA; Patarroyo ME
Vaccine; 2007 May; 25(22):4487-501. PubMed ID: 17403557
[TBL] [Abstract][Full Text] [Related]
10. Structural characterisation of sporozoite components for a multistage, multi-epitope, anti-malarial vaccine.
Patarroyo ME; Cifuentes G; Rodríguez R
Int J Biochem Cell Biol; 2008; 40(3):543-57. PubMed ID: 17997122
[TBL] [Abstract][Full Text] [Related]
11. Designing peptide-based vaccine candidates for Plasmodium falciparum erythrocyte binding antigen 175.
Chauhan S; Kumar R; Khan N; Verma S; Sehgal R; Tripathi PK; Farooq U
Biologicals; 2020 Sep; 67():42-48. PubMed ID: 32718776
[TBL] [Abstract][Full Text] [Related]
12. Malaria vaccine development using synthetic peptides as a technical platform.
Corradin G; Céspedes N; Verdini A; Kajava AV; Arévalo-Herrera M; Herrera S
Adv Immunol; 2012; 114():107-49. PubMed ID: 22449780
[TBL] [Abstract][Full Text] [Related]
13. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.
Lalvani A; Moris P; Voss G; Pathan AA; Kester KE; Brookes R; Lee E; Koutsoukos M; Plebanski M; Delchambre M; Flanagan KL; Carton C; Slaoui M; Van Hoecke C; Ballou WR; Hill AV; Cohen J
J Infect Dis; 1999 Nov; 180(5):1656-64. PubMed ID: 10515829
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in the development of a chemically synthesised anti-malarial vaccine.
Curtidor H; Patarroyo ME; Patarroyo MA
Expert Opin Biol Ther; 2015; 15(11):1567-81. PubMed ID: 26239009
[TBL] [Abstract][Full Text] [Related]
15. Stage-specific processing of Pfs230, a Plasmodium falciparum transmission-blocking vaccine candidate.
Williamson KC; Fujioka H; Aikawa M; Kaslow DC
Mol Biochem Parasitol; 1996 Jun; 78(1-2):161-9. PubMed ID: 8813686
[TBL] [Abstract][Full Text] [Related]
16. Based on HLA-DR beta1* allele binding specificities, striking differences in distance and TCR Contacting Residue Orientation can be observed in modified protection-inducing malarial synthetic peptides.
Patarroyo ME; Cifuentes G; Salazar LM; Espejo F; Alba MP; Bermúdez A
Curr Med Chem; 2005; 12(24):2849-65. PubMed ID: 16305475
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
[TBL] [Abstract][Full Text] [Related]
18. Conserved Binding Regions Provide the Clue for Peptide-Based Vaccine Development: A Chemical Perspective.
Curtidor H; Reyes C; Bermúdez A; Vanegas M; Varela Y; Patarroyo ME
Molecules; 2017 Dec; 22(12):. PubMed ID: 29231862
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
20. Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria.
Ballou WR; Kester KE; Heppner DG
Chem Immunol; 2002; 80():253-61. PubMed ID: 12058643
[No Abstract] [Full Text] [Related]
[Next] [New Search]
